Ibritumomab tiuxetan, also sold under the trade name Zevalin® is a monoclonal antibody radioimmunotherapy treatment for some forms of non-Hodgkin's lymphoma, a myeloproliferative disorder of the lymphatic system. This drug uses the parent mouse antibody to Rituxan (another treatment for lymphoma) call tositumomab, and adds it to radioactive isotopes Yttrium (Y-90) or Indium (In-111). The antibody binds to the CD20 antigen found on the surface of B cells, letting radiation from isotope (mostly beta emittion) to kill that cell and some surrounding cells. This eliminates B cells (including the cancerous ones) from the body, allowing a new population of healthy B cells to develop from lymphoid stem cells. more...
Administered by intravenous infusion which usually lasts around 10 minutes. Treatment with Zevalin (which also includes Rituxan) showed higher response rates in clinical trials compared to treatment with only Rituxan, and showed very promising results for patients who no longer respond to Rituxan.
Developed by the IDEC Pharmaceuticals Corporation, which is now part of Biogen Idec, Ibritumomab Tiuxetan was the first radioimmunotherapy drug approved by the FDA in 2002 to treat cancer.
Also see Bexxar, another monoclonal antibody radioimmunotherapy treatment of non-Hodgkin's lymphoma.
Read more at Wikipedia.org